CLOs on the Move

ConjuGon Inc

www.conjugon.com

 
ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.conjugon.com
  • University Research Park 505 S Rosa Rd Ste 29
    Madison, WI USA 53719
  • Phone: 608.441.2890

Executives

Name Title Contact Details

Similar Companies

VinCro Clinical Management Services

VinCro Clinical Management Services is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Deep Genomics

Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

GluStitch

GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.